NCT06982859

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 95 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.

Conditions

• Diabetes Mellitus
• Insulin Sensitivity

Interventions

Type	Name	Description
DRUG	Retatrutide	Administered SC
DRUG	Semaglutide	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2025-06-02
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2025-05-21
• Last updated: 2026-03-03

Locations

1 site across 1 country: Germany